Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
Hospital da Criança Santo Antônio, Porto Alegre, Rio Grande do Sul, Brazil
Dept. of Ophthalmology, HaEmek medical center, Afula, Israel
Cardiovascular Institute and Fuwai Hospital, Beijing, China
West Coast Clinical Trials, Cypress, California, United States
Centre Chirurgical Marie Lannelongue, Plessis-Robinson, France
Hospital Vall d'Hebron de Barcelona, Barcelona, Spain
Hospital de Getafe, Getafe, Madrid, Spain
Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
University of Alberta Hospital, Royal Alexandra Hospital, Edmonton, Alberta, Canada
The Hospital for Sick Children, Toronto, Ontario, Canada
Laleh Eslamian, Tehran, Iran, Islamic Republic of
Yonsei Univ., Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.